



### **Expected results**

1. Standardization and harmonization of research tools as applied to basic, animal and clinical research related to microbicide and vaccine. Verifiable aspects will be the development core protocols, provision of standardized reagents and the establishment of a quality assurance program.
2. The development of a portfolio of existing and new prevention candidates (vaccines, microbicides, and combinations) that can be evaluated on a side-by-side basis to prioritise the most promising leads for progression into translational clinical research. Verifiable indicators will be the development of an evolving portfolio of prevention candidates and their progress through preclinical evaluation.
3. Provision of an accessible toolbox to support translation of HIV-1 vaccine or microbicidal products from basic research in the European Research Area (ERA) into clinical trials. Verifiable indicators will be the accessibility and utility of the translational toolbox.
4. The increased competitiveness of European research in the fields of HIV-1 vaccine and microbicide research. Verifiable indicators will be workshop and conference attendance, scientific exchange and attainment of high degrees.
5. The development of an Internet resource that will be used by EUROPRISE participants and the scientific community. Verifiable indicators will be the utility and maintenance of the EUROPRISE web site.
6. Effective integration and identity of European microbicide and vaccine research. Verifiable indicators will be: an increase in collaborative research, publications, new joint research proposals; active engagement of community groups; and strong international representation of EU HIV prevention (conferences, expert panels, advisory boards, and publication of consensus documents).